Healthcare innovation requires curiosity

Curiosity is a critical yet underrated skill for 21st century healthcare innovation, according to a post on the HL7 blog authored by a writer known as HealthIsCool.

New ideas represent uncertainty so people shy aware. But, people in healthcare can drive more innovation by developing their curiosity, she wrote.

Building the capacity for inquiry can help develop the skill of curiosity. Asking questions is an opportunity to learn. In fact, a love of learning is vital for the new age, she wrote, citing Vivek Wadhwa, an author, academic, researcher and entrepreneur. Wadhwa says everyone needs to have a passion for continuous learning. “The sense of empathy that comes from music, arts, literature, and psychology provides a big advantage in design.”

The post also cited researchers at UC Berkeley who found that when doctors were genuinely curious about their patients’ perspectives, they significantly improved decision-making on both ends, and increased the effectiveness of treatment. Team-based healthcare can benefit from curiosity because “we need to cross-pollinate ideas and not be afraid to ask questions. When you start with a question, you can take a complex problem to small, actionable steps.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.